Tradestie Institutional Equity Comparison Engine

MRNA vs ALNY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ALNY Overall Edge

ALNY Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alnylam Pharmaceuticals, Inc. (ALNY) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus ALNY at 14.5x Forward P/E and 19.5% operating margin (+16.7% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against ALNY sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ALNY
MRNA 23.0x vs ALNY 14.5x Fwd P/E
Growth & Margin Winner ALNY
Op Margin -80.8% vs 19.5% ยท YoY +29.2% vs +16.7%
Momentum & Technical Winner MRNA
1Y +706.5% vs -68.8% ยท 52W Pos 67% vs 0%
Options & Structure Winner ALNY
CONSOLIDATION (52nd %ile IV) vs BREAKDOWN (23rd %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
ALNY NASDAQ
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$143.82
-2.71% 1D
Market Cap $19.8B
1M Return -36.72%
1Y Return -68.79%
Forward P/E 14.5x
Unified AI Score
48.8 / 100 HOLD
Tech 45.0 Fund 59.0 Flow 68.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% ALNY -68.79% Spread: +775.24 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MRNA Revenue ALNY Revenue MRNA Op. Margin ALNY Op. Margin Margin Edge
FY2018 $140M $70M -306.0% -1087.6% MRNA
FY2019 $60M $220M -906.8% -427.5% ALNY
FY2020 $800M $490M -95.0% -168.1% MRNA
FY2021 $18.5B $840M 72.0% -83.9% MRNA
FY2022 $19.3B $1.04B 48.9% -75.7% MRNA
FY2023 $6.85B $1.83B -61.9% -15.4% ALNY
FY2024 $3.24B $2.25B -121.9% -7.9% ALNY
FY2025 $1.94B $3.71B -158.1% 13.5% ALNY

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (4) vs ALNY (6)
Institutional Metric MRNA ALNY Criterion Row Winner
Market Capitalization Scale $80.7B $19.8B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 7.5x Lower Multiple ALNY
Forward P/E Ratio Valuation 23.0x 14.5x Lower Multiple ALNY
Revenue Growth (YoY) Growth +29.2% +16.7% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 19.5% Higher Margin ALNY
Net Profit Margin Profitability -110.5% 52.8% Higher Margin ALNY
Return on Equity (ROE) Capital Efficiency -34.5% 138.1% Higher ROE ALNY
52-Week Range Position Momentum 67% ($22โ€“$281) 0% ($143โ€“$477) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.54ฮฒ ยท 94% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 48.8 / 100 (HOLD) Higher Composite ALNY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs ALNY Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ALNY BREAKDOWN
56d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live ALNY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor ALNY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.